Windlas Biotech

Windlas Biotech ROE

The Return on Equity (ROE) of Windlas Biotech (WINDLAS.NS) as of Oct 19, 2026 is 11.44 %. In the previous year, Return on Equity (ROE) was 12.06 % — a change of -5.13% (lower).

ROE

11.44 %

YoY

-5.13%

Last updated:

In 2026, Windlas Biotech's return on equity (ROE) was 11.44 %, a -5.13% increase from the 12.06 % ROE in the previous year.

The Windlas Biotech ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
32.97 INR
Jan 1, 2020
7.73 INR
Jan 1, 2021
7.95 INR
Jan 1, 2022
9.65 INR
Jan 1, 2023
10.60 INR
Jan 1, 2024
12.93 INR
Jan 1, 2025
12.06 INR
Jan 1, 2026
11.44 INR
The Windlas Biotech ROE history
YEARROEYoY
11.44 %-5.13%
12.06 %-6.75%
12.93 %+22.04%
10.60 %+9.83%
9.65 %+21.35%
7.95 %+2.82%
7.73 %-76.54%
32.97 %+268.13%
8.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Windlas Biotech Stock analysis

What does Windlas Biotech do? Windlas Biotech Ltd is a contract development and manufacturing organization based in Dehradun, Uttarakhand, India. Listed on the National Stock Exchange with ticker WINDLAS.NS, the company employs 1,049 full-time staff. It provides comprehensive CDMO services, including product discovery, development, licensing, and commercial manufacturing of generic products, with a focus on complex generics. The firm specializes in therapeutic areas such as anti-diabetic, cardiovascular, neuropsychiatry, and respiratory treatments. Its capabilities cover formulation development, technology scale-up, and full-scale commercial manufacturing for both solid and liquid pharmaceutical dosage forms. Beyond contract services, Windlas markets its own nutraceutical, pharmaceutical, and Ayurvedic products to semi-urban and rural communities through a salesforce and distribution network spanning over 14 states. The company conducted its initial public offering on August 16, 2021. Windlas Biotech is one of the most popular companies on Eulerpool.

ROE Details

Decoding Windlas Biotech's Return on Equity (ROE)

Windlas Biotech's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Windlas Biotech's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Windlas Biotech's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Windlas Biotech’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Windlas Biotech stock

Return on Equity (ROE) of Windlas Biotech is 11.44 % in 2026.

Return on Equity (ROE) of Windlas Biotech changed from 12.06 % to 11.44 %, representing a -5.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Windlas Biotech since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Windlas Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Windlas Biotech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Windlas Biotech